Interferon-α salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation.
10.1007/s11684-017-0599-3
- Author:
Xiaodong MO
1
;
Xiaohui ZHANG
1
;
Lanping XU
1
;
Yu WANG
1
;
Chenhua YAN
1
;
Huan CHEN
1
;
Yuhong CHEN
1
;
Wei HAN
1
;
Fengrong WANG
1
;
Jingzhi WANG
1
;
Kaiyan LIU
1
;
Xiaojun HUANG
2
Author Information
1. Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.
2. Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China. huangxiaojun@bjmu.edu.cn.
- Publication Type:Journal Article
- Keywords:
donor lymphocyte infusion;
hematopoietic stem cell transplantation;
interferon-α;
minimal residual disease
- MeSH:
Adolescent;
Adult;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Beijing;
Child;
Child, Preschool;
Female;
Graft Survival;
Graft vs Host Disease;
mortality;
Hematopoietic Stem Cell Transplantation;
Humans;
Interferon-alpha;
therapeutic use;
Leukemia, Myeloid, Acute;
mortality;
therapy;
Lymphocyte Transfusion;
Male;
Middle Aged;
Myelodysplastic Syndromes;
mortality;
therapy;
Neoplasm, Residual;
Recurrence;
Salvage Therapy;
Survival Analysis;
Transplantation Conditioning;
Transplantation, Homologous;
Young Adult
- From:Frontiers of Medicine
2019;13(2):238-249
- CountryChina
- Language:English
-
Abstract:
The efficacy of salvage interferon-α (IFN-α) treatment was investigated in patients with unsatisfactory response to minimal residual disease (MRD)-directed donor lymphocyte infusion (DLI) (n = 24). Patients who did not become MRD-negative at 1 month after DLI were those with unsatisfactory response and were eligible to receive salvage IFN-α treatment within 3 months of DLI. Recombinant human IFN-α-2b injections were subcutaneously administered 2-3 times a week for 6 months. Nine (37.5%), 6 (25.0%), and 3 (12.5%) patients became MRD-negative at 1, 2, and > 2 months after the salvage IFN-α treatment, respectively. Two-year cumulative incidences of relapse and non-relapse mortality were 35.9% and 8.3%, respectively. Two-year probabilities of event-free survival, disease-free survival, and overall survival were 51.6%, 54.3%, and 68.0%, respectively. Outcomes of patients subjected to salvage IFN-α treatment after DLI were significantly better than those with persistent MRD without IFN-α treatment. Moreover, clinical outcomes were comparable between the salvage DLI and IFN-α treatment groups. Thus, salvage IFN-α treatment may help improve the outcome of patients with unsatisfactory responses to MRD-directed DLI and could be a potential salvage treatment for these patients after allogeneic hematopoietic stem cell transplantation.
